S&P 500   4,292.45 (+0.20%)
DOW   33,589.25 (+0.05%)
QQQ   355.17 (+0.09%)
AAPL   178.86 (-0.20%)
MSFT   332.50 (-0.35%)
META   270.45 (-0.25%)
GOOGL   127.12 (-0.15%)
AMZN   126.73 (+0.09%)
TSLA   228.20 (+3.11%)
NVDA   387.62 (+0.28%)
NIO   7.79 (-1.14%)
BABA   85.99 (-0.82%)
AMD   124.49 (+0.21%)
T   15.69 (+0.13%)
F   12.99 (+0.46%)
MU   69.47 (+2.86%)
CGC   0.76 (+3.16%)
GE   106.53 (+1.01%)
DIS   92.55 (+0.42%)
AMC   4.78 (+3.02%)
PFE   38.37 (-0.72%)
PYPL   65.29 (+0.42%)
NFLX   412.56 (+3.32%)
S&P 500   4,292.45 (+0.20%)
DOW   33,589.25 (+0.05%)
QQQ   355.17 (+0.09%)
AAPL   178.86 (-0.20%)
MSFT   332.50 (-0.35%)
META   270.45 (-0.25%)
GOOGL   127.12 (-0.15%)
AMZN   126.73 (+0.09%)
TSLA   228.20 (+3.11%)
NVDA   387.62 (+0.28%)
NIO   7.79 (-1.14%)
BABA   85.99 (-0.82%)
AMD   124.49 (+0.21%)
T   15.69 (+0.13%)
F   12.99 (+0.46%)
MU   69.47 (+2.86%)
CGC   0.76 (+3.16%)
GE   106.53 (+1.01%)
DIS   92.55 (+0.42%)
AMC   4.78 (+3.02%)
PFE   38.37 (-0.72%)
PYPL   65.29 (+0.42%)
NFLX   412.56 (+3.32%)
S&P 500   4,292.45 (+0.20%)
DOW   33,589.25 (+0.05%)
QQQ   355.17 (+0.09%)
AAPL   178.86 (-0.20%)
MSFT   332.50 (-0.35%)
META   270.45 (-0.25%)
GOOGL   127.12 (-0.15%)
AMZN   126.73 (+0.09%)
TSLA   228.20 (+3.11%)
NVDA   387.62 (+0.28%)
NIO   7.79 (-1.14%)
BABA   85.99 (-0.82%)
AMD   124.49 (+0.21%)
T   15.69 (+0.13%)
F   12.99 (+0.46%)
MU   69.47 (+2.86%)
CGC   0.76 (+3.16%)
GE   106.53 (+1.01%)
DIS   92.55 (+0.42%)
AMC   4.78 (+3.02%)
PFE   38.37 (-0.72%)
PYPL   65.29 (+0.42%)
NFLX   412.56 (+3.32%)
S&P 500   4,292.45 (+0.20%)
DOW   33,589.25 (+0.05%)
QQQ   355.17 (+0.09%)
AAPL   178.86 (-0.20%)
MSFT   332.50 (-0.35%)
META   270.45 (-0.25%)
GOOGL   127.12 (-0.15%)
AMZN   126.73 (+0.09%)
TSLA   228.20 (+3.11%)
NVDA   387.62 (+0.28%)
NIO   7.79 (-1.14%)
BABA   85.99 (-0.82%)
AMD   124.49 (+0.21%)
T   15.69 (+0.13%)
F   12.99 (+0.46%)
MU   69.47 (+2.86%)
CGC   0.76 (+3.16%)
GE   106.53 (+1.01%)
DIS   92.55 (+0.42%)
AMC   4.78 (+3.02%)
PFE   38.37 (-0.72%)
PYPL   65.29 (+0.42%)
NFLX   412.56 (+3.32%)

Gossamer Bio (GOSS) Stock Forecast, Price & News

$1.25
+0.03 (+2.46%)
(As of 06/6/2023 ET)
Compare
Today's Range
$1.19
$1.28
50-Day Range
$0.98
$1.53
52-Week Range
$0.91
$15.20
Volume
1.03 million shs
Average Volume
1.87 million shs
Market Capitalization
$119.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.32

Gossamer Bio MarketRank™ Forecast

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
485.5% Upside
$7.32 Price Target
Short Interest
Bearish
21.14% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.67
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Acquiring Shares
$802,713 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.87) to ($1.47) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.35 out of 5 stars

Medical Sector

210th out of 982 stocks

Pharmaceutical Preparations Industry

95th out of 484 stocks


GOSS stock logo

About Gossamer Bio (NASDAQ:GOSS) Stock

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 25, 2015 and is headquartered in San Diego, CA.

Receive GOSS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter.

GOSS Stock News Headlines

Nevada Desert more Valuable than Wall Street or Silicon Valley?
It could be true, according to Nevada Governor Steve Sisolak. The state's desert flats contain more lithium than any other geography in the world. And with electric vehicles driving a global boom in demand for lithium-ion batteries, Nevada should be on every investor's radar.
Gossamer Bio GAAP EPS of -$0.52 beats by $0.02
Nevada Desert more Valuable than Wall Street or Silicon Valley?
It could be true, according to Nevada Governor Steve Sisolak. The state's desert flats contain more lithium than any other geography in the world. And with electric vehicles driving a global boom in demand for lithium-ion batteries, Nevada should be on every investor's radar.
Gossamer Bio (GOSS) Receives a Buy from H.C. Wainwright
Wedbush Reaffirms Their Buy Rating on Gossamer Bio (GOSS)
Gossamer Bio, Inc. (NASDAQ:GOSS) Short Interest Update
Gossamer Bio, Inc. (NASDAQ:GOSS) CEO Buys $173,743.49 in Stock
See More Headlines

GOSS Price History

GOSS Company Calendar

Last Earnings
3/17/2023
Today
6/07/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GOSS
Fax
N/A
Employees
185
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.32
High Stock Price Forecast
$17.00
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+485.5%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
10 Analysts

Profitability

Net Income
$-229,380,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.13 per share

Miscellaneous

Free Float
86,377,000
Market Cap
$119.30 million
Optionable
Not Optionable
Beta
1.20

Key Executives

  • Faheem Hasnain
    Chairman, President & Chief Executive Officer
  • Bryan GiraudoBryan Giraudo
    Chief Operating & Financial Officer
  • Christian Waage
    EVP-Technical Operations & Administration
  • Richard Aranda
    Chief Medical Officer
  • Laura CarterLaura Carter
    Chief Scientific Officer













GOSS Stock - Frequently Asked Questions

Should I buy or sell Gossamer Bio stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gossamer Bio in the last year. There are currently 1 sell rating, 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GOSS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GOSS, but not buy additional shares or sell existing shares.
View GOSS analyst ratings
or view top-rated stocks.

What is Gossamer Bio's stock price forecast for 2023?

10 brokerages have issued twelve-month price targets for Gossamer Bio's shares. Their GOSS share price forecasts range from $1.50 to $17.00. On average, they expect the company's share price to reach $7.32 in the next twelve months. This suggests a possible upside of 485.5% from the stock's current price.
View analysts price targets for GOSS
or view top-rated stocks among Wall Street analysts.

How have GOSS shares performed in 2023?

Gossamer Bio's stock was trading at $2.17 at the beginning of 2023. Since then, GOSS stock has decreased by 42.4% and is now trading at $1.25.
View the best growth stocks for 2023 here
.

When is Gossamer Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our GOSS earnings forecast
.

How were Gossamer Bio's earnings last quarter?

Gossamer Bio, Inc. (NASDAQ:GOSS) posted its earnings results on Friday, March, 17th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.62) by $0.03.

What ETF holds Gossamer Bio's stock ?

WisdomTree BioRevolution Fund holds 2,078 shares of GOSS stock, representing 0.08% of its portfolio.

What other stocks do shareholders of Gossamer Bio own?
When did Gossamer Bio IPO?

(GOSS) raised $230 million in an IPO on Friday, February 8th 2019. The company issued 14,400,000 shares at a price of $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI served as the underwriters for the IPO.

What is Gossamer Bio's stock symbol?

Gossamer Bio trades on the NASDAQ under the ticker symbol "GOSS."

Who are Gossamer Bio's major shareholders?

Gossamer Bio's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.02%), Palo Alto Investors LP (3.63%), Platinum Investment Management Ltd. (2.48%), Acadian Asset Management LLC (2.32%), Two Sigma Investments LP (1.96%) and Two Sigma Advisers LP (1.93%). Insiders that own company stock include Bryan Giraudo, Caryn Peterson, Faheem Hasnain, Laura Carter, Luisa Salter-Cid, Richard Aranda and Waage Christian.
View institutional ownership trends
.

How do I buy shares of Gossamer Bio?

Shares of GOSS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gossamer Bio's stock price today?

One share of GOSS stock can currently be purchased for approximately $1.25.

How much money does Gossamer Bio make?

Gossamer Bio (NASDAQ:GOSS) has a market capitalization of $119.30 million. The company earns $-229,380,000.00 in net income (profit) each year or ($2.50) on an earnings per share basis.

How many employees does Gossamer Bio have?

The company employs 185 workers across the globe.

How can I contact Gossamer Bio?

Gossamer Bio's mailing address is 3013 SCIENCE PARK, SAN DIEGO CA, 92121. The official website for the company is www.gossamerbio.com. The company can be reached via phone at (858) 684-1300 or via email at ir@gossamerbio.com.

This page (NASDAQ:GOSS) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -